Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Urology Case Reports|January 23, 2023
A nontraditional presentation and treatment for emphysematous cystitisBenjamin Becker, Asher George, Ryan OwenCutis|September 21, 2018
Inflammatory linear verrucous epidermal nevus responsive to 308-nm excimer laser treatmentElise Grgurich, Naeha Gupta, Ryan Owen, et al.World Journal of Gastroenterology|August 29, 2006
Alpha-1-antitrypsin deficiency resulting in a hitherto unseen presentation of hepatocellular carcinoma: polycythemia but with normal alpha fetoproteinDavid Ryan Owen, Ramachandran Sivakumar, Eui-Sik Suh, et al.Peptides|January 7, 2004
A nonpeptide provides insight into mechanisms that regulate Drosophila melanogaster heart contractionsMelissa Mispelon, Kiran Thakur, Leslie Chinn, et al.Case Reports in Nephrology and Dialysis|March 12, 2021
Collapsing FSGS with Concurrent Class 2 and 3 Lupus Nephritis: A Case Report and Review of the LiteratureAimen Vanood, Ryan Owen, Marina Maraskine, et al.The AAPS Journal|June 2, 2023
Population-Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic AsthmaRui Zhu, Xiaoning Wang, Eric Anderson, et al.Journal of Clinical Pharmacology|October 24, 2022
Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic StrokeFei Tang, Jurgen Langenhorst, Steve Dang, et al.CPT: Pharmacometrics & Systems Pharmacology|March 10, 2023
PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticariaElise Oh, Russ Wada, Kha Le, et al.British Journal of Clinical Pharmacology|August 7, 2024
Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European UnionRui Zhu, Rik Schoemaker, Aurelie Gautier, et al.BMC Pulmonary Medicine|January 9, 2019
A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteersTracy L Staton, Kun Peng, Ryan Owen, et al.Pageof 2